Hlc 723g8 automatic glycosylated hemoglobin analyzer

We obtained information of general clinical characteristics from the electronic medical records system. Physical measurements consist of age, gender, diabetes duration, height, weight, Systolic blood pressure(SBP), diastolic blood pressure (DBP), diabetic complications, and status of insulin administration. Body mass index (BMI) was calculated as weight (kg)/height (m)². Laboratory examinations including hemoglobin A1C (HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), serum albumin (Alb), serum urea nitrogen (BUN), and serum creatinine (Scr), uric acid (UA). HbA1c was determined by high performance liquid chromatography (HLC-723G8 Automatic glycosylated hemoglobin Analyzer, TOSOH, Japan). All the above biochemical indices were tested under fasting conditions for more than 10 h. Previous or present smokers were considered to have smoked. Criteria for diagnosing diabetic kidney disease (DKD) was based on urinary albumin-to-creatinine ratio (ACR) being over 30 mg/g by at least two examinations. Diabetic retinopathy (DR) was determined by the same ophthalmologist through fundus examination and stereofundus photography after pupillary dilation.

Venous blood sample were collected in the morning following an overnight fast. Sociodemographic characteristics, physical examination information and laboratory measurements such as gender, age, durations, body mass index (BMI), serum uric acid (SUA), blood lipid, blood pressure, liver and kidney function parameters and blood glucose were collected by trained doctors. HbA1c was determined by high performance liquid chromatography (HLC-723G8 Automatic glycosylated hemoglobin Analyzer, TOSOH, Japan). Biochemical indexes were measured by automatic biochemical analyzer (Model 7600 Series Automatic Analyzer, Hitachi, Japan). Insulin and C-peptide concentrations were measured by electricity chemiluminescent immunoassay (IMMULITE 2000 XPi, Siemens, Germany) and glucagon was measured by radioimmunoassay (RIA, Millipore, Billerica, MA, USA). Serum OCN levels were evaluated by the electrochemiluminescence immunoassay method on a Roche COBAS E 801 (Roche Diagnostics Corporation, Mannheim, Germany).